Skip to main content
. 2019 Jan 11;41(6):356–363. doi: 10.1016/j.bj.2018.10.004

Table 3.

The pediatric sleep questionnaire (PSQ) variables before and after 6-months treatment of MPH in ADHD children.

Variables ADHD-I (n = 35)
ADHD-C (n = 36)
Total (n = 71)
Before treatment After treatment p value Before treatment After treatment p value Before treatment After treatment p value
Delay initiation of sleep, n (%) 14 (40) 14 (40) 0.985 11 (30.6) 8 (22.2) 0.542 25 (35.2) 22 (31.0) 0.592
Sleep onset latency, min [mean (SD)] 20.76 (19.89) 15.82 (13.29) 0.304 28.33 (20.88) 19.18 (15.69) 0.059 24.22 (20.48) 17.5 (13.8) 0.021a
Sleep fragment, n (%) 1 (2.9) 0 (0) 0.055 4 (11.1) 3 (8.3) 0.661 5 (7.0) 3 (4.2) 0.050
Total sleep time in weekday, h [mean (SD)] 8.55 (0.80) 8.59 (0.98) 0.668 8.80 (0.82) 8.64 (0.77) 0.396 8.68 (0.81) 8.61 (0.84) 0.516
Total sleep time in weekend, h [mean (SD)] 9.74 (1.27) 9.70 (1.01) 0.898 9.62 (1.04) 9.78 (1.32) 0.570 9.68 (1.15) 9.75 (1.19) 0.722
Daytime sleepiness, n (%) 6 (17.1) 4 (11.43) 0.413 6 (16.7) 4 (11.11) 0.552 12 (16.9) 8 (11.3) 0.152
Enuresis, n (%) 7 (20) 4 (11.43) 0.198 9 (25) 9 (25.0) 0.821 16 (22.5) 13 (18.3) 0.325
Bruxism, n (%) 17 (48.6) 10 (28.57) 0.022a 13 (36.1) 15 (41.67) 0.621 30 (42.3) 25 (35.2) 0.454
Sleep walking, n (%) 4 (11.4) 3 (8.57) 0.468 2 (5.6) 3 (8.3) 0.576 6 (8.4) 6 (8.5) 0.912
Nightmare, n (%) 7 (20) 7 (20) 0.914 10 (27.8) 5 (13.89) 0.021a 17 (23.9) 12 (16.9) 0.134
Obstructive sleep apnea, n (%) 2 (5.7) 1 (2.86) 0.357 1 (2.8) 2 (5.56) 0.236 3 (4.2) 3 (4.2) 0.998
Periodic limb movement disorder, n (%) 10 (28.6) 1 (2.86) 0.007a 8 (22.2) 1 (2.78) 0.020a 18 (25.4) 2 (2.8) 0.029a
Snoring, n (%) 12 (34.3) 9 (25.71) 0.046a 14 (38.9) 16 (44.4) 0.640 26 (36.6) 25 (35.2) 0.745

Delay initiation of sleep is sleep onset latency more than 30 mins.

Abbreviations: PSG: polysomnography; ADHD-I: ADHD with predominantly inattentive presentation; ADHD-C: ADHD with predominantly hyperactive/impulsive or combined presentation; MPH: methylphenidate; SD: standard deviation.

a

Indicate significant difference when compared with base-line pre-treatment data, with a p value of less than .05.